Return to site

Presence of skilled professional in the hospital care setting drives the grwoth of parkinsons disease treatment market

The Parkinson’s disease treatment market was valued at USD 3.99 billion in 2016 and expected to grow at a CAGR of 6.1% from 2017 to 2022 to reach USD 5.69 billion in 2022

· Pharmaceuticals

Hospitals segment is estimated to account for the largest share of the Parkinson’s disease treatment market in 2017. This segment includes large, medium-sized, and small hospitals as well as critical care centers. Growth in this market can largely be attributed to the patient visits to hospitals are very high owing to the availability of diagnostic laboratories for diagnosing diseases; and presence of skilled professionals.


Clinics, also known as outpatient clinics or ambulatory care clinics, are healthcare facilities where outpatients are treated. In comparison with hospitals, clinics are expected to hold a smaller share of the overall market in the coming years mainly due to the shortage of neurologists in these facilities. In addition, most clinics do not have in-house diagnostic laboratories, owing to which most patients prefer hospitals.

Teva (Israel), AbbVie (US), Boehringer Ingelheim (Germany) Lundbeck (Denmark), Acadia (US), Sun Pharma (India), US WorldMeds (US), Dr. Reddy’s (India), are the top players in this market. These companies have a broad product portfolio with comprehensive features and a strong geographical presence.

raph text here.

Target Audience

  • Parkinson’s disease treatment product manufacturers
  • Parkinson’s disease treatment dealers and suppliers
  • Human identification service providers
  • Parkinson’s disease associations
  • Academic institutions
  • Venture capitalists
  • Consulting firms
  • Government bodies
Parkinson’s disease treatment market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by Europe, followed by North America, however, the Asian region is expected to witness the highest growth during the forecast period.
Asia is expected to witness the highest CAGR, with the growth in this market centered at Japan, China, and India. The increasing number of generic drug manufacturers and rising aging populaion across are key factors driving the Parkinson’s disease treatment market in Asia. However, availability of alternative treatments is going to restrain this market.
All Posts

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OKSubscriptions powered by Strikingly